Inmagene Biopharmaceuticals has started a proof-of-concept trial of the pipeline drug IMG-007 in adult patients with moderate-to-severe atopic dermatitis (AD).
The clinical stage biotechnology company based in Shanghai has dosed the first patient in a Phase I/II global multicentre proof-of-concept (POC) study (NCT05984784) of IMG-007. The study will assess the safety, pharmacokinetics, and efficacy of IMG-007 in AD patients.
In a single ascending dose study in healthy adults which has already been completed, IMG-007 demonstrated a half-life that exceeded the average for conventional IgG antibodies. A target serum concentration is maintained for approximately 12 to 18 weeks after a single dose which allows patients to have longer drug holidays. IMG-007 is the lead compound in development by Inmagene.
Chief medical officer of Inmagene, Yufang Lu said: “IMG-007 represents an investigational drug with multiple potential indications. We are excited to begin this trial of IMG-007 in AD patients, following favourable safety and highly differentiated pharmacokinetic results of the earlier trial.
“We are continuing our evaluations of IMG-007’s potential in other diseases where OX40 signalling pathway plays an important pathogenic role.”
What is IMG-007
IMG-007 is a humanised IgG1 monoclonal antibody (mAb) that specifically binds to the OX40 receptor. OX40-OX40L axis is important in T cell activation, expansion, and survival. In nonclinical studies, Inmagene reports that IMG-007 potently and completely blocked signalling between OX40 and OX40L. The Fc region of the drug has been bioengineered, resulting in an extended half-life and a silenced antibody-dependent cell-mediated cytotoxicity (ADCC) function.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataOther pipeline drugs
Inmagene is developing three other clinical-stage drug candidates, IMG-004, IMG-008 and IMG-020. IMG-004 is a non-covalent, reversible BTK inhibitor being trialled in patients with multiple sclerosis and completing Phase I clinical development.
IMG-008 is a long-acting mAb against IL-36R and is entering global Phase I clinical development. It is being trialled in patients with hidradenitis suppurativa and generalised pustular psoriasis.
Finally, IMG-020, also referred to as izokibep, is an anti-IL-17 small protein therapeutic in global clinical development for a number of indications including hidradenitis suppurativa, psoriatic arthritis, uveitis, psoriasis and axial spondyloarthritis.
